Cargando…

Elimination of infectious HIV DNA by CRISPR–Cas9

Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelon...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Atze T, Binda, Caroline S, Berkhout, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050564/
https://www.ncbi.nlm.nih.gov/pubmed/31450074
http://dx.doi.org/10.1016/j.coviro.2019.07.001
_version_ 1783502631621099520
author Das, Atze T
Binda, Caroline S
Berkhout, Ben
author_facet Das, Atze T
Binda, Caroline S
Berkhout, Ben
author_sort Das, Atze T
collection PubMed
description Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelong treatment. Therefore, novel therapeutic strategies are being investigated that aim to permanently inactivate the proviral DNA, which may lead to a cure. Multiple studies showed that CRISPR–Cas9 genome editing can be used to attack HIV DNA. Here, we will focus on not only how this endonuclease attack can trigger HIV provirus inactivation, but also how virus escape occurs and this can be prevented.
format Online
Article
Text
id pubmed-7050564
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-70505642020-03-02 Elimination of infectious HIV DNA by CRISPR–Cas9 Das, Atze T Binda, Caroline S Berkhout, Ben Curr Opin Virol Article Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelong treatment. Therefore, novel therapeutic strategies are being investigated that aim to permanently inactivate the proviral DNA, which may lead to a cure. Multiple studies showed that CRISPR–Cas9 genome editing can be used to attack HIV DNA. Here, we will focus on not only how this endonuclease attack can trigger HIV provirus inactivation, but also how virus escape occurs and this can be prevented. 2019-08-23 2019-10 /pmc/articles/PMC7050564/ /pubmed/31450074 http://dx.doi.org/10.1016/j.coviro.2019.07.001 Text en This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Das, Atze T
Binda, Caroline S
Berkhout, Ben
Elimination of infectious HIV DNA by CRISPR–Cas9
title Elimination of infectious HIV DNA by CRISPR–Cas9
title_full Elimination of infectious HIV DNA by CRISPR–Cas9
title_fullStr Elimination of infectious HIV DNA by CRISPR–Cas9
title_full_unstemmed Elimination of infectious HIV DNA by CRISPR–Cas9
title_short Elimination of infectious HIV DNA by CRISPR–Cas9
title_sort elimination of infectious hiv dna by crispr–cas9
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050564/
https://www.ncbi.nlm.nih.gov/pubmed/31450074
http://dx.doi.org/10.1016/j.coviro.2019.07.001
work_keys_str_mv AT dasatzet eliminationofinfectioushivdnabycrisprcas9
AT bindacarolines eliminationofinfectioushivdnabycrisprcas9
AT berkhoutben eliminationofinfectioushivdnabycrisprcas9